ReProtect  Products to protect reproductive health

Welcome
About ReProtect
Contact ReProtect
News
Glossary
Site Map

Publications

Ballagh SA, Brache V, Mauck C, Callahan MM, Cochon L, Wheeless A, Moench TR.
A Phase I study of the functional performance, safety and acceptability of the BufferGel Duet.
Contraception. 2008 Feb;77(2):130-7. Epub 2007 Dec 27.

Barnhart KT, Rosenberg MJ, MacKay HT, Blithe DL, Higgins J, Walsh T, Wan L,Thomas M, Creinin MD,Westhoff C, Schlaff W, Archer DF, Ayers C, Kaunitz A, Das S, Moench TR.
Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trial.
Obstet Gynecol. 2007 Sep;110(3):577-86.

Achilles SL, Shete PB, Whaley KJ, Moench TR, Cone RA. Microbicide efficacy and toxicity tests in a mouse model for vaginal transmission of Chlamydia trachomatis. Sex Transm Dis. 2002;29:655-64.

Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, Moench TR.
Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis. 2006 Jun 1;6:90.

Harwell JI, Moench T, Mayer KH, Chapman S, Rodriguez I, Cu-Uvin S.
A pilot study of treatment of bacterial vaginosis with a buffering vaginal microbicide.
J Womens Health (Larchmt). 2003 Apr;12(3):255-9.

Mayer KH, Peipert J, Fleming T, Fullem A, Moench T, Cu-Uvin S, Bentley M, Chesney M, Rosenberg Z.
Safety and tolerability of BufferGel®, a novel vaginal microbicide, in women in the United States Clin. Infect. Dis. 2001, 32: 476-482.

Moench TR, Chipato T, Padian NS.
Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices.
AIDS 2001, 15: 1595-1602.

Olmsted SS, Khanna KV, Ng EM, Whitten ST, Johnson ON 3rd, Markham RB, Cone RA, Moench TR. Low pH immobilizes and kills human leukocytes and prevents transmission of cell-associated HIV in a mouse model. BMC Infect Dis. 2005 Sep 30;5:79.

Olmsted SS, Dubin NH, Cone RA, Moench TR.
The rate at which human sperm are immobilized and killed by mild acidity.
Fertil. Steril. 2000 73(4):687-693.

Tabet SR, Callahan MM, Mauck CK, Gai F, Coletti AS, Profy AT, Moench TR, Soto-Torres LE, Poindexter III AN, Frezieres RG, Walsh TL, Kelly CW, Richardson BA, Van Damme L, Celum CL.
Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men.
J Acquir Immune Defic Syndr. 2003 Aug 1;33(4):476-83. Erratum in: J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):118.

van de Wijgert J, Fullem A, Kelly C, Mehendale S, Rugpao S, Kumwenda N, Chirenjo Z, Joshi S, Taha T, Padian N, Bollinger R, Nelson K.
Phase 1 trial of the topical microbicide BufferGel : safety results from four international sites.
J. AIDS 2001, 26: 41-27.

Zeitlin L, Hoen TE, Achilles SL, Hegarty TA, Jerse AE, Kreider JW, Olmsted SS, Whaley KJ, Cone RA, Moench TR.
Tests of BufferGel for contraception and prevention of sexually transmitted diseases in animal models.
Sexually Transmitted Dis. 2001;28: 417-423.

Science

 
Last updated 11/24/08  |  Legal Information  |  Copyright ReProtect Inc., 2003-2008